{"product_id":"azzalure-125-units-double","title":"Azzalure 125 units Dual","description":"\u003ch1\u003eAzzalure® 125 Speywood Units\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003eBotulinum Toxin Type A | Prescription Only Medicine\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAzzalure® 125 Speywood units is a prescription-only medicinal product containing \u003cstrong\u003ebotulinum toxin type A (Clostridium botulinum toxin A haemagglutinin complex)\u003c\/strong\u003e. It is supplied as a white powder for solution for injection and requires reconstitution before administration.\u003c\/p\u003e\n\u003cp\u003eEach vial contains \u003cstrong\u003e125 Speywood units\u003c\/strong\u003e of botulinum toxin type A. Azzalure Speywood units are specific to this preparation and \u003cstrong\u003emust not be converted or considered interchangeable with units of other botulinum toxin products\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch2\u003eLicensed indications\u003c\/h2\u003e\n\u003cp\u003eAzzalure is licensed for the temporary improvement in the appearance of moderate to severe:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eGlabellar lines\u003c\/strong\u003e — vertical lines between the eyebrows seen at maximum frown\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eLateral canthal lines\u003c\/strong\u003e — commonly referred to as crow's feet, seen at maximum smile\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe licensed indication applies to adult patients under 65 years where the severity of the lines has an important psychological impact.\u003c\/p\u003e\n\u003ch2\u003eWhy Azzalure?\u003c\/h2\u003e\n\u003cp\u003eAzzalure has an established clinical evidence base in the treatment of glabellar and lateral canthal lines. In clinical studies, the median onset of response for glabellar lines was \u003cstrong\u003e2–3 days\u003c\/strong\u003e, with an optimal effect demonstrated for up to \u003cstrong\u003e4 months\u003c\/strong\u003e following treatment. Some patients remained responders at 5 months.\u003c\/p\u003e\n\u003cp\u003eFor lateral canthal lines, clinical studies demonstrated a statistically significant reduction in severity compared with placebo at 4, 8 and 12 weeks following treatment.\u003c\/p\u003e\n\u003cp\u003eAzzalure has also been studied with repeated treatment cycles, with clinical data supporting maintained efficacy across repeated treatments.\u003c\/p\u003e\n\u003cp\u003eThese clinical outcomes should be considered alongside individual patient assessment, treatment suitability and the current prescribing information.\u003c\/p\u003e\n\u003ch2\u003eProduct information\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eProduct:\u003c\/strong\u003e Azzalure® 125 Speywood units\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eActive ingredient:\u003c\/strong\u003e Botulinum toxin type A\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eStrength:\u003c\/strong\u003e 125 Speywood units per vial\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePharmaceutical form:\u003c\/strong\u003e Powder for solution for injection\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eRoute of administration:\u003c\/strong\u003e Intramuscular\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eLegal category:\u003c\/strong\u003e Prescription Only Medicine (POM)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePack sizes:\u003c\/strong\u003e 1 or 2 vials\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eMarketing Authorisation Holder:\u003c\/strong\u003e Galderma (U.K.) Limited\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eUK product licence:\u003c\/strong\u003e PL 00538\/0101\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eReconstitution\u003c\/h2\u003e\n\u003cp\u003eAzzalure must be reconstituted using \u003cstrong\u003esodium chloride 9 mg\/ml (0.9%) solution for injection\u003c\/strong\u003e before administration.\u003c\/p\u003e\n\u003cp\u003eThe current SmPC provides dilution instructions for achieving the required concentration. Reconstitution and administration should be undertaken using appropriate aseptic technique by a healthcare practitioner with the relevant qualifications and expertise.\u003c\/p\u003e\n\u003ch2\u003eStorage\u003c\/h2\u003e\n\u003cp\u003eStore Azzalure in a refrigerator at \u003cstrong\u003e2°C–8°C\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eDo not freeze.\u003c\/p\u003e\n\u003cp\u003eThe current SmPC states that an unopened vial can be exposed to temperatures up to \u003cstrong\u003e25°C for a single period of up to 72 hours\u003c\/strong\u003e, after which it should be returned to refrigerated storage for the remainder of its shelf life.\u003c\/p\u003e\n\u003cp\u003eFollowing reconstitution, chemical and physical in-use stability has been demonstrated for \u003cstrong\u003e24 hours at 2°C–8°C\u003c\/strong\u003e. From a microbiological perspective, the product should be used immediately where possible.\u003c\/p\u003e\n\u003ch2\u003eProfessional supply\u003c\/h2\u003e\n\u003cp\u003eSupplied by \u003cstrong\u003eLongeva Pharmacy\u003c\/strong\u003e to eligible UK healthcare professionals, subject to appropriate professional verification, prescription and applicable supply requirements.\u003c\/p\u003e\n\u003cp\u003eAzzalure should only be administered by a healthcare practitioner with appropriate qualifications and expertise in its use and with the required equipment. The product is intended for treatment of \u003cstrong\u003eone patient during a single treatment session\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eProfessional supply only. Prescription required.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch2\u003eImportant prescribing information\u003c\/h2\u003e\n\u003cp\u003eHealthcare professionals should consult the current \u003cstrong\u003eAzzalure 125 Speywood units Summary of Product Characteristics (SmPC)\u003c\/strong\u003e before prescribing, preparing or administering the product.\u003c\/p\u003e\n\u003cp\u003eThe SmPC contains full information regarding contraindications, warnings and precautions, adverse reactions, dosage, administration, interactions, storage and handling requirements.\u003c\/p\u003e\n\u003cp\u003eSuspected adverse reactions should be reported through the \u003cstrong\u003eMHRA Yellow Card Scheme\u003c\/strong\u003e.\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Double Vial","offer_id":57717410431324,"sku":"6613f26daa745","price":140.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1018\/4923\/5804\/files\/Azzalure.png?v=1781877803","url":"https:\/\/longevapharma.com\/products\/azzalure-125-units-double","provider":"Longeva Pharma","version":"1.0","type":"link"}